Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in FLT3-ITD/ NPM1wt Patients - a Study By the NOPHO-DB-SHIP Consortium

Gertjan J.L. Kaspers, Noa E. Wijnen, Joost B. Koedijk, Sae Ishimaru, Renske Benedictus, Ellen C. Van Opstal, Harm Van Tinteren, C. Michel Zwaan, Noha Biserna, Pamela Downs, Yvonne Duong, Yasser Mostafa Kamel, Jonas Abrahamsson, Nira Arad-Cohen, Nicole Bodmer, Luis Castillo, Daniel Cheuk, Vitor Costa, Barbara De Moerloose, Jose Maria Fernandez NavarroLinda Fogelstrand, Bianca F. Goemans, Henrik Hasle, Olafur G. Jonsson, Zhanna Kovalova, Monica C. Munthe-Kaas, Ulrika Norén-Nyström, Sauli Palmu, Ramune Pasauliene, Kadri Saks, Anne Maria Tierens, Dominik Turkiewicz, Cornelis Jan Pronk

Research output: Contribution to journalMeeting Abstractpeer-review

5 Downloads (Pure)
Original languageEnglish
Article number 1532
JournalBlood
Volume142
Issue numberSuppl.1
DOIs
Publication statusPublished - 28 Nov 2023
Externally publishedYes
EventASH Annual Meeting - San Diego, United States
Duration: 9 Dec 202312 Dec 2023
https://www.hematology.org/newsroom/annual-meeting-press/press-kit/general-annual-meeting-information-and-materials

Field of Science*

  • 3.2 Clinical medicine

Publication Type*

  • 3.4. Other publications in conference proceedings (including local)

Cite this